Dror Bashan | executive |
Eyal Rubin | executive |
Raghuram Selvaraju | analyst |
John Vandermosten | analyst |
Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2024 Financial and Business Results Conference Call.
As a reminder, this conference call is being recorded.
I will now turn the conference over to our host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations for Protalix.
You may begin your conference.